BridgeBio

10/21/2026

"A major problem for rare disease research is funding." – Guangping Gao, M.D., UMass Chan Medical School

Noa is one of more than 30 million Americans living with a rare disease.

Fewer than 5% of rare diseases have an FDA-approved treatment. For most families, a diagnosis still arrives with no answer attached — and they wait.

Noa's Story is about what changed, and about the parents, researchers, and advocates who refused to accept that answer.

Our thanks to the Greenwood family for sharing Noa with us, and to the UMass Chan Medical School for the years of work behind this moment.

Watch the full video on our Insights page: https://bit.ly/4z9U5fL

10/16/2026

For people living with chronic and their caregivers, learning about a begins with clear, accessible information. Take a closer look at what researchers hope to learn through the RECLAIM-HP Study and how the study medicine is given.

10/14/2026

“The first thing that pops up is that life expectancy is about ten. That was when we realized how bad it really was.” – Lori Greenwood, Noa's mother

Noa is one of more than 30 million Americans living with a rare disease.

Fewer than 5% of rare diseases have an FDA-approved treatment. For most families, a diagnosis still arrives with no answer attached — and they wait.

Noa's Story is about what changed, and about the parents, researchers, and advocates who refused to accept that answer.

Our thanks to the Greenwood family for sharing Noa with us, and to the UMass Chan Medical School for the years of work behind this moment.

Watch the full video on our Insights page: https://bit.ly/4z9U5fL

10/13/2026

10/09/2026

"You're still a person; you still have feelings." 💬

This , meet Gwyn: a college student, future dietitian, and host of the podcast A Little View. On this episode of the , Gwyn talks candidly about growing up with , body image, and how community helped her find her voice. Now she uses her own experiences to help others.

Listen to the full conversation: https://bit.ly/47M9tTK

10/09/2026

People living with chronic and their caregivers may have questions about clinical and what researchers hope to learn. The RECLAIM-HP Study aims to learn whether the study medicine—taken by mouth twice a day—can help keep blood and urine calcium levels in the normal range.

10/07/2026

When 10-month-old Noa Greenwood was diagnosed with a rare genetic disease, her parents, Lee and Lori were confronted with an idea of a future they'd never prepared for; the likelihood that their daughter would not progress beyond the abilities of a six-month-old and may not live past her 10th birthday.

Noa is one of more than 30 million Americans living with a rare disease. Fewer than 5% of these diseases have an FDA-approved treatment, leaving the people behind these numbers waiting for a treatment.

Many rare diseases are comprised of relatively small patient populations, often considered too small a market for traditional pharma to fund; even when medical researchers had found potential therapies.

BridgeBio is built on a new model, finding therapies for rare genetic diseases using clearer biology, faster learning, and smarter financing. Noa's story is what that looks like in a single life and a reason for hope for the millions of families still waiting for answers.

10/06/2026

An important milestone in our work to support the achondroplasia community.

The FDA has accepted our application for Priority Review for infigratinib in achondroplasia and set a target action date of February 4, 2027.

We're grateful to the families, advocates, and investigators, who made this possible, and looking forward to expanding the options available for the community.